FDA Drug Risk Evaluation Deputy Avigan Is Gastrointestinal Specialist
Executive Summary
CDER Division of Drug Risk Evaluation Deputy Director Mark Avigan, MD, has expertise in gastrointestinal safety issues
You may also be interested in...
FDA Office Of Drug Safety Gets Two Permanent Division Directors
Two of the three divisions in FDA's Office of Drug Safety now have permanent directors
FDA Office Of Drug Safety Gets Two Permanent Division Directors
Two of the three divisions in FDA's Office of Drug Safety now have permanent directors
FDA Office Of Drug Safety Director-Designate Is ODE III Deputy Raczkowski
FDA Office of Drug Safety Director-designate Victor Raczkowski, MD, brings hands-on experience with the application of risk-management techniques from the review of GlaxoSmithKline's Lotronex